Sectors
TSHA
Taysha Gene Therapies, Inc.
5.62
11 x 5.61
7 x 5.62
bid
ask
-
0.05
0.93%
01:31 PM
timesize
| Ytd | 2.13% | |
| 1y | 113.58% |
5.55
day range
5.69
2.34
52 week range
7.30
| Open | 5.61 | Prev Close | 5.67 | Low | 5.55 | High | 5.69 | Mkt Cap | 1.42B |
| Vol | 594.63K | Avg Vol | 3.04M | EPS | -0.38 | P/E | -14.92 | Forward P/E | -14.57 |
| Beta | 1.17 | Short Ratio | 10.84 | Inst. Own | 86.20% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-06 | 50-d Avg | 6.05 | 200-d Avg | 5.22 | 1yr Est | 13.00 |
| Income Statement | |||
| Operating Expenses | 43.49M | ||
| Research and Development Expense | 33.81M | ||
| Selling, General and Administrative Expense | 9.68M | ||
| Operating Income | -43.49M | ||
| Interest Expense | 9.00K | ||
| Net Income | -42.41M | ||
| Net Income Common Stock | -42.41M | ||
| Net Income Common Stock (USD) | -42.41M | ||
| Consolidated Income | -42.41M | ||
| Earnings per Basic Share | -0.12 | ||
| Earnings per Basic Share (USD) | -0.12 | ||
| Earnings per Diluted Share | -0.12 | ||
| Earning Before Interest & Taxes (EBIT) | -42.40M | ||
| Earning Before Interest & Taxes (USD) | -42.40M | ||
| Weighted Average Shares | 366.63M | ||
| Weighted Average Shares Diluted | 366.63M | ||
| Balance Sheet | |||
| Cash and Equivalents | 279.34M | ||
| Cash and Equivalents (USD) | 279.34M | ||
| Current Assets | 282.25M | ||
| Property, Plant & Equipment Net | 15.61M | ||
| Total Assets | 300.35M | ||
| Total Debt | 66.73M | ||
| Current Liabilities | 20.10M | ||
| Debt Non-Current | 66.73M | ||
| Total Liabilities | 88.41M | ||
| Accumulated Retained Earnings (Deficit) | -753.71M | ||
| Accumulated Other Comprehensive Income | 985.00K | ||
| Shareholders Equity | 211.94M | ||
| Shareholders Equity (USD) | 211.94M | ||
| Assets Non-Current | 18.10M | ||
| Total Debt (USD) | 66.73M | ||
| Liabilities Non-Current | 68.31M | ||
| Trade and Non-Trade Payables | 4.56M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 580.00K | ||
| Net Cash Flow from Financing | 711.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -43.19M | ||
| Capital Expenditure | -24.00K | ||
| Issuance (Purchase) of Equity Shares | 692.00K | ||
| Net Cash Flow from Investing | -3.02M | ||
| Net Cash Flow from Operations | -40.88M | ||
| Share Based Compensation | 5.55M | ||